Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 32Cisplatin 23Cetuximab 14Carboplatin 13Magnetic Resonance Spectroscopy 12Specimen Handling 10Radiotherapy, Intensity-Modulated 10Paclitaxel 9Nivolumab 9Docetaxel 8Platinum 71,2-diaminocyclohexaneplatinum II citrate 7Radiotherapy 5Biopsy 5dostarlimab 4atezolizumab 4Immunoglobulin G 4Disulfides 4Bevacizumab 4(225)Ac-DOTA-c(RGDyK) 4cemiplimab 3Taxes 3Radiation 3Fulvestrant 3Fluorouracil 3budigalimab 2amivantamab 2abemaciclib 2Radiotherapy, Image-Guided 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × Toll-Like Receptor 1 × 30 days × Clear all
NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡